CAR-T细胞治疗在血液系统恶性肿瘤中的研究进展

doi:10.11904/j.issn.1002-3070.2016.05.018

实用肿瘤学杂志 ›› 2016, Vol. 30 ›› Issue (5): 473-476.doi: 10.11904/j.issn.1002-3070.2016.05.018

CAR-T细胞治疗在血液系统恶性肿瘤中的研究进展

桑秀莉, 史策综述, 周晋审校

哈尔滨医科大学附属第一医院血液内科(哈尔滨 150000)

收稿日期:2016-03-05 出版日期:2016-10-28 发布日期:2016-11-02
通讯作者: 周晋,E-mail:zhoujin1111@126.com
作者简介:桑秀莉,女,(1990-),硕士研究生,从事生物治疗方面的研究

The research development of Chimeric Antigen Receptor T-cells in hematological malignancies

SANG Xiuli, SHI Ce, ZHOU Jin

The First Affiliated Hospital Harbin Medical University,Harbin 150001,China

Received:2016-03-05 Online:2016-10-28 Published:2016-11-02

摘要/Abstract

摘要： 嵌合抗原受体T(CAR-T)细胞是近年来迅速发展的肿瘤过继性免疫治疗新手段。其主要特点是通过基因工程改造获得识别肿瘤抗原特异性受体的T细胞并赋予其靶向性、杀伤性及持久性的治疗方法。1989年首次提出CAR-T,现已经发展到第四代,且多研究中心对CD19-CAR-T细胞治疗技术进行了Ⅰ期临床研究显示出活性。CAR-T疗法是目前有望治愈复发难治性血液肿瘤的新方法。

关键词: CAR-T细胞治疗, 血液系统, 恶性肿瘤

Abstract: In recent years,chimeric antigen receptor T-cells(CAR-T cells)therapy becomes the new rapid development of adoptive tumor immunotherapy.Its main characteristic is to identify specific T cell receptor of tumor antigen by genetic engineering modification and give its targeting,killing and persistent treatment.The CAR-T was mentioned for the first time in 1989,and has developed to the fourth generation.CD19-CAR-T treatment technique shows activity in phase I clinical trials of multiple research centers.CAR-T therapy is expected as a new way to cure relapse/refractory hematological malignancies.

Key words: Chimeric antigen receptor T-cells, Hematological, Malignancy

中图分类号:

R392

桑秀莉, 史策综述, 周晋审校. CAR-T细胞治疗在血液系统恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2016, 30(5): 473-476.

SANG Xiuli, SHI Ce, ZHOU Jin. The research development of Chimeric Antigen Receptor T-cells in hematological malignancies[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(5): 473-476.

参考文献

1 Melenhorst JJ,Levine BL.Innovation and opportunity for chimeric antigen receptor targeted T cells[J].Cytotherapy,2013,15(9):1046-1053.
2 应巧红,钱慧芳.CART技术治疗血液恶性肿瘤研究进展[J].现在医药卫生,2015,31(21):3256-3259.
3 钱磊,崔久嵬.嵌合型抗原受体基因修饰的 T 细胞研究进展[J].中国免疫学杂志,2014,30(6):850-857.
4 张鸿声.嵌合抗原受体 T 细胞肿瘤治疗的前生、今世和将来[J].转化医学杂志,2015,3(3):129-133.
5 Chen R,Song XT,Chen B.CD19 chimeric antigen receptor T cell therapy for the treatment of B cell lineage acute lymphoblastic leukemia[J].Discov Med,2015,20(110):185-190.
6 常征,陈学武,王丽,等.嵌合抗原受体T细胞治疗恶性肿瘤的研究进展[J].药学研究,2015,34(9):534-536.
7 Tasian SK,Gardner RA.CD19-redirected chimeric antigen receptor-modified T cells:a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia(ALL)[J].Ther Adv Hematol,2015,6(5):228-241.
8 Maude SL,Teachey DT,Porter DL,et al.CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia[J].Blood,2015,125(26):4017-4023.
9 Singh H,Figliola MJ,Dawson MJ,et al.Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using sleeping beauty system and artificial antigen presenting cell[J].PLoS One,2013,8(5):e64138.
10 Leen AM,Rooney CM,Foster AE.Improving T cell therapy for cancer[J].Annu Rev Immunol,2007,25:243-265.
11 赵嫄,胡婉丽,张连生.嵌合抗原受体疗法在血液肿瘤免疫治疗中的研究进展与应用前景[J].中华临床医师杂志,2014,8(6):1158-1161.
12 Stephen JS,Jakub S,Sunita DN,et al.Sustained remissions following chimeric antigen receptor modified T cells directed against CD19(CTL019)in patients with relapsed or refractory CD19+ lymphomas[R].Orlando:Orange County Convention Center,2015.
13 Topp MS,Kufer P,Gokbuget N,et al.Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival[J].J Clin Oncol,2011,29(18):2493-2498.
14 Lee DW,Kochenderfer JN,Stetler-Stevenson M,et al.T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults:a phase 1 dose-escalation trial[J].Lancet,2015,385(9967):517-528.
15 Grupp SA,Kalos M,Barrett D,et al.Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J].N Engl J Med,2013,368(16):1509-1518.
16 Gardner RA,Jensen MC.CD19CAR T cells:from humble beginnings to cancer immunotherapy′s poster child[J].Cancer J,2014,20(2):107-111.
17 Kebriaei P,Huls H,Singh H,et al.Adoptive therapy using sleeping beauty gene transfer system andartificial antigen presenting cells to manufacture T cells expressing CD19-specific chimeric antigen receptor[R].San Francisco:Moscone West Convention Center,2014.
18 Lee DW,Gardner R,Porter DL,et al.Current concepts in the diagnosis and management of cytokine release syndrome[J].Blood,2014,124(2):188-195.
19 Maude SL,Barrett D,Teachey DT,et al.Managing cytokine release syndrome associated with novel T cell-engaging therapies[J].Cancer,2014,20(2):119-122.
20 Maude SL,Frey N,Shaw PA,et al.Chimeric antigen receptor T cells for sustained remissions in leukemia[J].N Engl J Med,2014,371(16):1507-1517.
21 Marco R,David MB,Saad SK,et al.Combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells for the treatment and prevention of antigen-loss relapses occurring CD19 targeted immunotherapies[R].Orlando:Orange County Convention Center,2015.
22 Mardiros A,Forman SJ,Budde LE,et al.T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia[J].Curr Opin Hematol,2015,22(6):484-488.
23 Pinz K,Liu H,Golightly M,et al.Preclinical targeting of human T cell malignancies using CD4-specific chimeric antigen receptor(CAR)-engineered T cells[J].Leukemia,2016,30(3):701-707.
24 Topp M,Gokbuget N,Zugmaier G,et al.Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia[J].J Clin Oncol,2014,32(36):4134-4140.

[1]	张茂祥,孙惠昕,宋冰冰. 2008—2012年哈尔滨市道里区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2019, 33(3): 261-265.
[2]	李诚, 兰莉, 杨超, 张婷婷, 王蕊, 林琳, 田文静. 2015—2017年哈尔滨市恶性肿瘤发病与死亡特征分析[J]. 实用肿瘤学杂志, 2019, 33(1): 62-66.
[3]	韩滕综述, 唐丽萍审校. PD-L1的表达与妇科恶性肿瘤预后关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 468-470.
[4]	韩帮岭, 汪亦民, 薛英威. 中性粒细胞与恶性肿瘤关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(4): 349-352.
[5]	周洁, 陈钰(综述), 陈道桢(审校). 纳米材料在肿瘤光动力治疗中的应用[J]. 实用肿瘤学杂志, 2018, 32(3): 245-249.
[6]	侯思宇(综述), 陈秀玮(审校). JMJD2B蛋白结构功能及在恶性肿瘤发生发展中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(3): 250-253.
[7]	张婷, 侯光营, 王鑫(综述), 贺岩(审校). QKI蛋白在恶性肿瘤中的研究进展及临床意义[J]. 实用肿瘤学杂志, 2018, 32(3): 263-266.
[8]	纪巧, 陈丽(综述), 何远桥(审校). 三维组织药敏法在肿瘤个体化精准医疗中的应用[J]. 实用肿瘤学杂志, 2018, 32(3): 280-284.
[9]	李静,张云艳. miR-331-3p在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(2): 125-129.
[10]	张永欣, 黄河. Galectin-9与多种恶性肿瘤的研究进展及作用机制探讨[J]. 实用肿瘤学杂志, 2018, 32(2): 159-163.
[11]	吴逸飞, 刘宝刚. 硫氧还蛋白还原酶2在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(2): 174-178.
[12]	韩雪娇, 李艳春, 孙立春, 鲁海玲审校. 14-3-3ζ与恶性肿瘤关系的研究进展[J]. 实用肿瘤学杂志, 2017, 31(6): 543-547.
[13]	江莹, 刘宝刚审校. RCAN1在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2017, 31(6): 559-563.
[14]	孙禹琪,陈秀玮. CTGF/CCN2在恶性肿瘤的发生发展及靶向治疗中的研究进展[J]. 实用肿瘤学杂志, 2017, 31(4): 363-366.
[15]	霍明娟,孟祥程,孙影,程丽. ALCAM在妇科恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2017, 31(4): 381-384.

CAR-T细胞治疗在血液系统恶性肿瘤中的研究进展

The research development of Chimeric Antigen Receptor T-cells in hematological malignancies

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价